Abbott is named global industry leader in sustainability for the sixth consecutive year on the Dow Jones Sustainability Index (DJSI)

AbbottFor the sixth consecutive year, Abbott (NYSE: ABT) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability and responsibility. As the industry leader in Health Care Equipment & Supplies, Abbott is one of the 60 companies recognized for leading their respective global industries.

The DJSI designation recognizes companies for responsible and sustainable business, including economic, social and environmental performance. This is the 14th consecutive year that Abbott has been recognized for sustainability through its inclusion on the DJSI, including both the Dow Jones Sustainability World Index and North America Index.

"As a healthcare company, we recognize that the success of our business depends upon a range of factors - economic, social and environmental. Our work is aligned with the United Nations Sustainable Development Goals to ensure our efforts are focused on the needs deemed most important to global well-being," said Miles D. White, chairman and chief executive officer, Abbott. "This year marks Abbott's 130th anniversary. That long history of success gives us a particular appreciation for sustainability, and what it takes to achieve it. We will continue to bring that perspective and that commitment to our efforts to be a productive and responsible corporate citizen."

Abbott earned the highest industry scores in economic and social performance. The company's score of 82 was more than double the average score of 33 for other companies in the industry.

Abbott also achieved the top industry scores in nine of DJSI's 24 specific economic, social and environmental criteria, including corporate governance; talent attraction and retention; marketing practices; customer relationship management; health outcome contribution; tax strategy; environmental reporting and social reporting; and corporate citizenship and philanthropy.

In addition to being included in the Dow Jones Sustainability Index for 14 years, Abbott was recently named to the Fortune magazine "Change the World" list for creating positive social impact through business. The company also was named one of the 100 Best Corporate Citizens by Corporate Responsibility magazine for 10 consecutive years, and was named the 2018 Corporate Citizen of the Year by the Executives' Club of Chicago. To learn more about Abbott's sustainability initiatives and reporting, please visit www.abbott.com/sustainability.

About ABOUT S&P Dow Jones Indices

The Dow Jones Sustainability Indices (DJSI) are maintained collaboratively by S&P Dow Jones Indices (S&P DJI), one of the world's leading index providers, and RobecoSAM, the investment specialist that has focused exclusively on Sustainability Investing (SI) for over 23 years. Launched in 1999, the DJSI World represents the gold standard for corporate sustainability and is the first global index to track the leading sustainability-driven companies based on RobecoSAM's analysis of financially material Environmental, Social, and Governance (ESG) factors and S&P DJI's robust index methodology. RobecoSAM assesses the world's largest companies via its annual Corporate Sustainability Assessment (CSA), which uses a consistent, rules-based methodology to convert an average of 600 data points per company into one overall score. This score determines inclusion in the DJSI.

About Abbott

At Abbott, we're committed to helping people live their best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 99,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

Most Popular Now

Novartis announces plan to initiate clinical trial…

Novartis today announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the effic...

Sanofi and Regeneron provide update on U.S. Phase …

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzar...

Gilead announces results from Phase 3 trial of inv…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigation...

AstraZeneca and Oxford University announce landmar…

AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine a...

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Loss of smell associated with milder clinical cour…

Following an earlier study that validated the loss of smell and taste as indicators of SARS-CoV-2 infection, researchers at UC San Diego Health report in newly published ...

Can an existing HIV medication slow the spread of …

A team of scientists from St. Michael's Hospital, Sinai Health and Sunnybrook Health Sciences Centre have launched a clinical trial to understand whether an existing drug...